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Abstract
Background: The CC-chemokine receptor-3 (CCR3) has emerged as a target molecule for pharmacological
intervention in allergic inflammation.
Objective: To examine whether a dual CCR3 and H1-receptor antagonist (AZD3778) affects allergic inflammation
and symptoms in allergic rhinitis.
Methods: Patients with seasonal allergic rhinitis were subjected to three seven days’ allergen challenge series.
Treatment with AZD3778 was given in a placebo and antihistamine-controlled design. Symptoms and nasal peak
inspiratory flow (PIF) were monitored in the morning, ten minutes post challenge, and in the evening. Nasal
lavages were carried out at the end of each challenge series and a2-macroglobulin, ECP, and tryptase were
monitored as indices of allergic inflammation.
Results: Plasma levels of AZD3778 were stable throughout the treatment series. AZD3778 and the antihistamine
(loratadine) reduced rhinitis symptoms recorded ten minutes post challenge during this period. AZD3778, but not
the anti-histamine, also improved nasal PIF ten minutes post challenge. Furthermore, scores for morning and
evening nasal symptoms from the last five days of the allergen challenge series showed statistically significant
reductions for AZD3778, but not for loratadine. ECP was reduced by AZD3778, but not by loratadine.
Conclusions: AZD3778 exerts anti-eosinophil and symptom-reducing effects in allergic rhinitis and part of this
effect can likely be attributed to CCR3-antagonism. The present data are of interest with regard to the potential
use of AZD3778 in allergic rhinitis and to the relative importance of eosinophil actions to the symptomatology of
allergic rhinitis.
Trial registration: EudraCT No: 2005-002805-21.
Background
The CC-chemokine receptor-3 (CCR3) is a transmem-
brane protein that constitutes one of the receptors for
CC-chemokines. It is localized to cells of key impor-
tance to allergic inflammation including dendritic cells,
Th2-lymphocytes, eosinophils, basophils, and mast cells
as well as to epithelial, smooth muscle, and neural cells
[1-7]. Chemokines interacting with CCR3 include
eotaxin-1, 2, and 3, MCP-4, and RANTES [8]. Stimula-
tion of the receptor produces chemotaxis and cellular
activation [8], and experiments in CCR3 knock-out mice
and such involving CCR3-neutralizing antibodies have
demonstrated the importance of the CCR3-pathway to
eosinophil activity in vivo [9-12]. CC-chemokines are
increased in allergic airway conditions [10,13-16].
Accordingly, CCR3 may be a treatment target in allergic
rhinitis and asthma. Recently, this possibility was sub-
stantiated by a report on symptom-reducing effects of
topical anti-sense therapy directed towards CCR3 in
asthma [17], although that particular study did not dis-
criminate between an effect on CCR3 and an effect
mediated through the common b-chain of the IL-3, IL-
5, and GM-CSF receptors.
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molecular weight CCR3-antagonists can reduce allergic
inflammation in vivo.W e g m a n net al., in a study invol-
ving ovalbumin-sensitized mice repeatedly challenged
with ovalbumin to produce inflammation, showed that a
CCR3-antagonist reduced BAL and tissue eosinophila
and that this effect was associated with normalization of
airway reactivity and prevention of goblet cell hyperpla-
sia [18]. Das et al. reported that two separate CCR3-
antagonists reduced eotaxin-elicited and allergen-
induced eosinophil recruitment to bronchial airways in
an experimental murine model [19]. Nakamura et al., in
a mouse model of allergic conjunctivitis, demonstrated
that a highly selective CCR3-antagonist attenuated early
and late phase symptoms [20], suggesting a symptom-
reducing potential in allergic conditions, and that the
effect was associated with mast cell stabilization. Addi-
tional observations on effects of CCR3-antagonists com-
prise prevention of immediate and late-phase allergic
skin reactions to allergen in a mouse allergy model [21],
inhibition of eosinophil infiltration into the airways of
monkeys following segmental bronchial provocation
with eotaxin [22], and dose-dependent reduction of eosi-
nophil recruitment into the lungs in an animal model of
allergic airway inflammation [23]. The examples above
highlight the anti-allergic potential of CCR3-antagonism.
However, observations on effects of CCR3-antagonists
on allergic inflammation in man are lacking. Hence,
explorations of CCR3-inhibition in man are highly
warranted.
AZD3778 is a novel small molecular weight dual
CCR3 and histamine H1-receptor antagonist. It has been
characterized by MDS Pharma Services (Taipei, Taiwan:
http://discovery.mdsps.com) in a battery of 226 assays
covering a diverse range of enzyme, transporter, and
receptor targets (not including CCR3). The only signifi-
cant activity detected (defined as >50% inhibition) was
against the guinea-pig H1-receptor with a Ki of 54 nM.
AZD3778 also has been shown to inhibit the binding of
a specific CCR3 radioligand,
125I-eotaxin, to the human
CCR3-receptor expressed on CHO-cells with a pIC50 of
8.1 ± 0.1 (mean ± SEM, equivalent to an IC50 of 8 nM.)
The functional potency of AZD3778 has been assessed
in test systems in which a response mediated by human
CCR3 could be evoked using human eotaxin 1 or 2. For
example, AZD3778 inhibited chemotaxis of eosinophils.
From in vitro experiments on whole blood, where
plasma protein binding would reduce the free fraction
of AZD3778, the A2 (the concentration of antagonist
required to produce a two-fold shift of the agonist
response) for CCR3 was 200 nM. AZD3778 also inhib-
i t e dt h eb i n d i n go fas p e c i f i cH 1-radioligand,
3H-pyrila-
min, to the human H1-receptor expressed on CHO-cells
with an IC50 of 40 nM. In human HeLa-cells expressing
the human H1-receptor, AZD3778 inhibited histamine-
induced calcium flux with an IC50 of 63 nM (expected
A2 in whole blood of 1000 nM). Taken together, the
above observations indicate that AZD3778 has CCR3
and H1-antagonistic properties.
In the present study, involving patients with allergic
rhinitis examined outside the pollen season in an aller-
gen challenge model [24,25], we examined whether
treatment with AZD3778 affected symptoms and signs
of allergic rhinitis. Accordingly, we monitored rhinitis
symptoms and nasal lavage fluid levels of ECP, reflecting
eosinophil activity, as well as tryptase and a2-macroglo-
bulin, reflecting mast cell activity and plasma exudation,
respectively. We have previously shown that nasal lavage
recovery of inflammatory mediators can be improved by
utilization of histamine-challenges. In this regard, hista-
mine produces a plasma exudation response that facili-
tates their luminal entry [25]. In the present study, we
aimed at using this experimental tool, but since
AZD3778 exerts H1-antagonistic effects we chose to
induce plasma exudation through nasal challenge with
bradykinin [26]. Finally, reflecting the H1-antagonistic
property of AZD3778, we compared the effect of this
drug to an anti-histamine (loratadine). We report on
symptom-reducing and anti-eosinophil effects that likely
can be attributed to CCR3-antagonism.
Methods
Study design
The study was of a randomized, double blind, placebo-
controlled (double-dummy), and three-way crossover
design. It comprised three ten days’ treatment periods
carried out in the pollen-free autumn/winter months
separated by at least two weeks washout-periods. The
treatments were AZD3778, loratadine, and placebo.
After three days of treatment, a series of seven indivi-
dualized, once-daily allergen challenges commenced
while the treatment continued. Nasal symptoms and
peak inspiratory flow (PIF) were recorded. In addition,
at the end of each treatment and allergen challenge ser-
ies, nasal lavages were carried out. Tryptase, ECP, and
a2-macroglobulin were measured as indices of mast cell
activity, eosinophil activity, and plasma exudation,
respectively. The study was approved by the Regional
Ethics Committee, Lund, and the Swedish Medical Pro-
duct Agency. It was conducted according to the
Declaration of Helsinki and in compliance with Good
Clinical Practice. Informed consent was obtained.
Subjects
Forty-six patients were enrolled and subjected to physi-
cal examination and skin prick test. Inclusion criteria:
Men and post-menopausal or surgically sterile women,
seasonal allergic rhinitis for at least two years, positive
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tomatic condition outside the pollen season, need for
treatment at seasonal allergen exposure, and a positive
response to nasal allergen challenge (see the titration
procedure below). Exclusion criteria: Any relevant dis-
ease including perennial allergic rhinitis, asthma, clini-
cally relevant structural nasal abnormalities, upper
respiratory tract infection within two weeks prior to the
start of the study, use of topical corticosteroids within
four weeks prior to the study and use of antihistamines
within one week, and immunotherapy. Of the 46 sub-
jects enrolled, 38 were randomized and received at least
one dose of a study drug. Of those randomized, 37 were
analyzed for efficacy. There were six withdrawals from
the study: One due to an adverse event and five because
of lack of compliance. Of the 38 subject allocated to
treatment, all were men. The average age was 25 years
(range 20-51) and average BMI was 24 kg/m
2 (range 20-
29). The median time since diagnosis of allergic rhinitis
was 14 years (range 2-33).
Treatment
AZD3778 (AstraZeneca, Lund, Sweden) was adminis-
tered as an oral suspension (300 mg twice daily). Lorata-
din Biochemie (Sandoz, Helsingborg, Sweden) was given
as a tablet (10 mg once daily). Placebo was a suspension
to match AZD3778 (AstraZeneca, Lund, Sweden) and a
tablet to match Loratadin Biochemie (AstraZeneca,
Charnwood, UK). Each treatment period comprised ten
days and compliance was assured by supervising admin-
istration on the first treatment day and thereafter by
control of daily diary recordings of intake of study medi-
cation. Allergen challenges (see below) were adminis-
tered during the last seven days of each treatment
period. On the first day of treatment as well as on days
eight, nine, and ten, pharmacokinetic samples (plasma)
were collected within two to five hours after drug
administration. Also, such samples were obtained before
drug administration on days eight, nine, and ten.
Allergen challenge model
In order to establish individually tolerable, repeatable,
yet symptom-producing allergen challenge-doses, a nasal
titration procedure was performed [24,25]. Increasing
doses of allergen were administrated at 10 min intervals
using a spray-device delivering 100 μL per actuation.
One puff was administered into each nostril resulting in
effective doses of 100, 300, 1.000, and 3.000 SQ units
per nasal cavity (Aquagen, ALK-Abelló, Horsholm, Den-
mark). This scheme was followed until the subject
responded with at least 5 sneezes or recorded a symp-
tom score of 2 or more on a scale from 0 to 3 for either
nasal secretion or nasal blockage. The dose that pro-
duced this effect was chosen for the allergen challenge
series and was given once daily for seven days. The
allergen challenge was administered two to five hours
after the morning dose of the study drug.
Clinical evaluation
The subjects scored nasal symptoms every morning and
evening, starting three days prior to each treatment and
continuing until day six after the last treatment day.
The scores were entered into diary cards and each regis-
tration reflected the preceding twelve hours. Nasal
secretion and blockage, respectively, as well as the most
severe of the symptoms sneezing and itching were each
scored on a four-grade scale where 0 = no symptoms, 1
= mild symptoms, 2 = moderate symptoms, and 3 =
severe symptoms. The scores were added to a daily total
nasal symptom score (TNSS), with separate scores for
morning and evening observations. Morning and eve-
ning scores, respectively, from the 5
th,6
th,a n d7
th aller-
gen-challenge day where added and divided by three
resulting in a mean TNSS based on three days’ observa-
tions (range 0-9). In addition, morning and evening
scores, respectively, from the 3
rd through 7
th allergen-
challenge day were added and divided by five resulting
in a mean TNSS based on five days’ observations (range
0-9). Nasal symptoms were also scored immediately
prior to and 10 min post allergen challenge: Secretion
and blockage were scored as described above, whereas
the number of sneezes were counted and transformed
into a sneezing score by the investigators: 0 sneezes = 0,
1-4 sneezes = 1, 5-9 sneezes = 2, and 10 or more
sneezes = 3. The scores were added to a daily post chal-
lenge TNSS, and a mean TNSS for post challenge symp-
tom scores calculated from observations made on the
5
th through 7
th challenge day as described above. The
subjects recorded nasal PIF in the morning, immediately
prior to and 10 min post allergen challenge, and in the
evening using a flow-meter (Clement-Clarke, Harlow, U.
K.) equipped with a facial mask. Mean nasal PIF, for
morning observations, observations immediately prior to
and 10 min post challenge, and evening observations,
respectively, from the last three days of each allergen
challenge series were calculated.
Nasal lavages and bradykinin challenges
A 2.5 min nasal lavage with isotonic saline was carried
o u ta tt h ef i r s ts t u d yv i s i tp r i o rt oa n yt r e a t m e n ta n d
prior to any allergen challenge (baseline observation).
Nasal lavages were also obtained twice on day seven of
each allergen challenge series. Accordingly, a 2.5 min
saline lavage was carried out first and this lavage was
separated from the allergen challenge on this particular
d a yb ya tl e a s t1h o u r .I tw a sf o l l o w e db yt w o3 0s e c
lavages carried out in order to remove remaining solutes
on the nasal mucosal surface. (These lavages were
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with bradykinin was performed (in order to improve the
recovery of inflammatory mediators [25].) and followed,
an additional 15 min later, by a final 2.5 min saline
lavage. Nasal lavages were carried out using a pool-
device containing 15 ml of isotonic saline [27]. The
lavage fluids were kept in the right nasal cavity at all
occasions. The recovered lavage fluid was centrifuged
and the supernatant was homogenized, prepared in ali-
quots, and frozen (-30°C). The bradykinin challenge
(100 μg) was carried out using a spray-device delivering
100 μL per actuation.
Analysis
a2-Macroglobulin was measured using a radioimmu-
noassay sensitive to 7.8 ng/mL. The intra- and inter-
assay coefficients of variation are between 3.8-6.0% and
3.1-7.2%, respectively [25]. ECP was measured using a
fluoroimmunoassay (Pharmacia-Diagnostics, Uppsala,
Sweden) with a sensitivity of 2.0 ng/mL. Tryptase was
measured using a radioimmunoassay with detection
limit of 0.5 ng/mL (Pharmacia-Diagnostics, Uppsala,
Sweden). a2-Macroglobulin and ECP were analyzed in
the lavage fluids as they were, whereas lavage fluids
samples were concentrated five times before the analysis
of tryptase.
Statistics
All hypothesis-testing was done using two-sided alterna-
tives at a 5% significance level. The comparison between
AZD3778 and placebo was primary and comparisons
versus loratadine secondary. Accordingly, no adjust-
ments for multiplicity were applied. The full analysis set
was used for all analyses, i.e., all subjects with evaluable
data collected from at least two treatment periods. In
total 37 of the 38 randomized subjects could be evalu-
ated for efficacy. Change in period means from baseline
(i.e., mean over the last three days of the run-in/wash-
out period that preceded the treatment period) to treat-
ment in symptom scores and nasal PIF recorded in the
diary were compared between treatment groups using
an analysis of variance model with subject, period, and
treatment as fixed factors and using baseline as a covari-
ate. Period means for symptoms and nasal PIF recorded
post-challenge, and variables from the nasal lavages,
were compared between treatment groups using analysis
of variance models with subject, period and treatment
as fixed factors.
Results
Pharmacokinetic observations
Plasma levels of AZD3778 were stable late into the
treatment series (Table 1). The minimum level recorded
was 0.3 μmol/L and a total of six pre-dose samples were
below the 3 × A2 level of 0.6 μmol/L over treatment
days 8, 9, and 10. The median trough plasma levels of
AZD3778 for days 8, 9, and 10 were 3.41, 2.79, and 2.95
μmol/L, respectively.
Post challenge symptom scores
During the last three days of the allergen challenge ser-
ies, AZD3778 and loratadine reduced post-challenge
mean TNSS (p < 0.001 and 0.001, respectively) (Tables
2 and 3). In addition, AZD3778, but not loratadine,
reduced post-challenge nasal blockage (p = 0.008, c.f.
placebo): mean scores for nasal blockage was 1.41, 1.52,
and 1.65 for AZD3778, loratadine, and placebo,
respectively.
Morning and evening symptom scores
The allergen challenge-induced change in mean TNSS
from baseline was lowest in the AZD3778 group during
last three days of the allergen challenge series, but treat-
ment comparisons did not reach statistically significant
differences for either AZD3778 or loratadine compared
with placebo: mean TNSS in the morning were 1.66,
1.98, and 2.00 for AZD3778, loratadine, and placebo,
respectively. Corresponding values for TNSS in the eve-
ning were 1.59, 1.86, and 1.72. Similarly, there were no
Table 1 Summary statistics on plasma concentrations of
AZD3778 (μmol/L).
Variable n Gmean CV Min Median Max
Day 1, post-dose 34 5.49 38.5 2.45 5.83 10.40
Day 8, pre-dose 24 2.51 98.0 0.29 3.41 6.27
Day 8, post dose 34 7.77 44.4 3.14 7.95 20.10
Day 9, pre-dose 26 2.21 106.4 0.32 2.79 8.13
Day 9, post dose 34 7.55 36.0 3.15 7.51 15.60
Day 10, pre-dose 34 2.53 71.0 0.28 2.95 7.84
Day 10, post dose 34 7.19 36.5 3.29 7.34 13.50
Plasma levels of AZD3778 were stable during the last three days of the
treatment series.
Table 2 Period means and ranges for pre- and 10 min
post-allergen challenge mean TNSS and mean nasal PIF
over the last three days of the allergen challenge series.
Pre challenge 10 min post challenge
Variable Treatment n Mean Range Mean Range
TNSS AZD3778 35 1.25 0, 3 4.11 0.7, 7.7
Loratadine 35 1.64 0, 8 3.85 1, 8
Placebo 34 1.56 0, 5.5 5.57 1.7, 9
Nasal
PIF
AZD3778 35 179 76.7, 247 125 50, 200
Loratadine 35 165 50, 243 114 30, 210
Placebo 34 177 100, 257 108 57, 177
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and evening nasal PIF (data not shown).
In contrast to the three-day observation period, mean
TNSS of the last five days of the allergen challenge ser-
ies showed statistically significant reductions in mean
TNSS differences between AZD3778 and placebo for
morning as well as evening observations (p = 0.023 and
0.022, respectively) (Tables 4 and 5). In contrast, no
such effects were observed for loratadine.
Lavage fluid observations
In the placebo run, nasal lavage fluid levels of tryptase,
ECP, and a2-macroglobulin were elevated in saline
lavage fluids collected late into the allergen challenge
series (c.f. baseline observation prior to the challenge
series) (Figure 1). Also, compared with the baseline as
well as with the saline lavage carried out late into the
allergen challenge series, bradykinin produced increased
levels of a2-macroglobulin (Figure 2).
Whereas loratadine failed to affect the lavage fluid
indices that were increased by the repeated allergen
challenges, AZD3778 reduced the levels of ECP com-
pared with placebo (Figure 3). For the lavage obtained
pre-bradykinin challenge, the numerical reduction in
ECP failed to reach statistical significance (Figure 3),
whereas the reduction was statistically significant for the
post-bradykinin observation (p = 0.038) (Figure 3). Also,
focusing on post-bradykinin observations, AZD3778
reduced the levels of ECP compared with loratadine (p
= 0.012) (Figure 3). Neither AZD3778 nor loratadine
reduced the levels of tryptase and a2-macroglobulin
(Figure 3).
Discussion
The present study demonstrates that a dual CCR3 and
histamine H1-receptor antagonist (AZD3778) can exert
anti-eosinophil and symptom-reducing effects in a con-
dition in man characterised by allergic airway inflamma-
tion. Our data are of interest with regard to the
pharmacology of CCR3-antagonism, the relative impor-
tance of eosinophil actions to the symptomatology of
allergic rhinitis, and the potential use of AZD3778 in
the treatment of allergic rhinitis.
Preceding in vitro studies performed by MDS Pharma
Services indicted that AZD3778 had a whole blood A2
at the CCR3-receptor of 0.2 μmol/L. Furthermore, with
regard to antagonism of the histamine H1-receptor, a
whole blood exposure of 1.0 μmol/L was equivalent to
A2. In the present study, plasma levels of AZD3778
were stable late into the treatment series. At trough, the
plasma concentration of AZD3778 suggested that expo-
sures were close to those required for 24-hour antagon-
ism of the CCR3 and H1-receptors.
It is difficult to compare treatment-effects in allergic
rhinitis during the pollen season, reflecting uncertainties
regarding onset and intensity of natural allergen
Table 3 Treatment comparisons for 10 min post
challenge mean TNSS and mean nasal PIF over the last
three days of the allergen challenge series.
Variable Treatment Mean
difference
a
95% CI P-
value
TNSS AZD3778 vs. placebo -1.56 -2.03, -1.09 <0.001
Loratadine vs.
placebo
-1.87 -2.34, -1.4 <0.001
AZD3778 vs.
loratadine
0.312 -0.149,
0.773
0.181
Nasal
PIF
AZD3778 vs. placebo 16.8 5.73, 27.9 0.004
Loratadine vs.
placebo
8.67 -2.43, 19.8 0.124
AZD3778 vs.
loratadine
8.14 -2.83, 19.1 0.143
aAdjusted mean difference from ANOVA.
AZD3778 as well as loratadine reduced post challenge TNSS. In addition,
AZD3778 improved post challenge nasal PIF.
Table 4 Period means and ranges for TNSS from the
diary cards: Period means over five days.
Baseline period Treatment period
Variable Treatment n Mean Range Mean Range
TNSS
-morning
AZD3778 35 0.581 0, 2 1.6 0.2, 4.67
Loratadine 35 0.829 0, 4 1.88 0, 7.2
Placebo 35 0.695 0, 3.33 2 0, 8
TNSS
-evening
AZD3778 35 0.486 0, 2 1.48 0, 4.33
Loratadine 35 0.743 0, 4 1.85 0, 8.6
Placebo 34 0.657 0, 3.33 1.88 0, 5.6
Table 5 Treatment comparisons for TNSS from the diary
cards: Period means over five days.
Variable Treatment Mean
difference
a
95% CI P-
value
TNSS
-morning
AZD3778 vs.
placebo
-0.459 -0.85,
-0.067
0.023
Loratadine vs.
placebo
-0.174 -0.569, 0.22 0.381
AZD3778 vs.
loratadine
-0.285 -0.685,
0.115
0.159
TNSS
-evening
AZD3778 vs.
placebo
-0.562 -1.04,
-0.083
0.022
Loratadine vs.
placebo
-0.172 -0.649,
0.305
0.474
AZD3778 vs.
loratadine
-0.39 -0.868,
0.088
0.108
AZD3778 reduced TNSS in the morning as well as in the evening.
aAdjusted mean difference from ANOVA.
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rate studies of crossover design and when resorting to
parallel group studies these are hampered by inter-indi-
vidual differences in allergen sensitivity. In order to
overcome these problems, we have introduced a model
where nasal challenges with individualized doses of
allergen are given for seven consecutive days to create a
repeatable artificial pollen season characterized by devel-
opment of rhinitis symptoms and allergic inflammation
[24,25]. In the present study, this model was used and
around-the-clock rhinitis symptoms were produced by
the allergen-challenges in the placebo-run. Notably,
symptom scores reached at placebo treatment were very
similar to those recorded previously in the model.
Using the mean over the last three days of the allergen
challenge series, based on previous evaluations in the
present model in which symptoms gradually increased
over time [24,25], AZD3778 reduced post-challenge
TNSS compared with placebo. In contrast, no statisti-
cally significant effects were observed for morning and
evening symptoms when focusing on this period. By
these characteristics, which were of the same profile and
magnitude as for anti-histamines: loratadine (this study)
and cetirizine [28], it might be suggested that AZD3778
acted through H1-antagonism or that CCR3-antagonism
resulted in the same effect-profile as that of anti-hista-
mines. However, AZD3778 also reduced post-challenge
nasal blockage and improved post-challenge nasal PIF.
Moreover, when focusing on the last five days of the
allergen challenge series (which was valid since an effect
plateau was reached already at allergen challenge day
three), AZD3778 exerted statistically significant reducing
effects also on morning and evening symptoms. These
latter effects, which were not observed for loratadine,
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Figure 1 A. Tryptase (A), ECP (B), and a2-macroglobulin (C) in
lavages obtained at baseline (before allergen challenge) and in
corresponding lavages late into the allergen challenge series
(prior to bradykinin challenge) in the placebo run (median
values with interquartile ranges). The allergen challenge series
produced an inflammatory response characterized by increased
mast cell and eosinophil activity as well as by plasma exudation.
(*Denotes p < 0.05, ***denotes p < 0.001, and ****denotes p <
0.0001.)
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Figure 2 a2-Macroglobulin in lavages obtained at baseline and
late into the allergen challenge series prior to and after
bradykinin challenge in the placebo run (median values with
interquartile ranges). Bradykinin produced plasma exudation, a
process that may facilitate luminal entry of tissue solutes including
tryptase and ECP. (****Denotes p < 0.0001.)
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anti-rhinitis effects. Accordingly, CCR3-antagonists may
have a potential as a treatment for allergic rhinitis.
From a therapeutic point of view, the possibility that
AZD3778 exerts CCR3 as well as H1-antagonistic effects
is attractive. However, compared with previous observa-
tions in the present model [24,25], the effect of
AZD3778 will likely be inferior that of a topical corti-
costeroid. Further studies are warranted to evaluate
AZD3778 and other CCR3-antagonists in allergic
rhinitis.
In the present placebo run, nasal lavage fluid levels of
ECP, tryptase, and a2-macroglobulin increased during
the allergen challenge series compared with baseline
data. This was in agreement with previous observations
in the present model and indicated a development of
allergic airway inflammation [25]. Whereas loratadine
failed to affect these indices, AZD3778 reduced the
levels of ECP compared with placebo. For the pre-brady-
kinin challenge lavage, the numerical 37% reduction in
ECP failed to reach statistical significance, whereas the
reduction was significant for the post-bradykinin obser-
vation. (Plasma exudation events acutely produced by
histamine is known to improve the recovery of tryptase
and ECP [25]: bradykinin was employed in the present
study to achieve this and its exudative effect was con-
firmed.) The effect of AZD3778 likely reflected CCR3-
antagonism and not H1-antagonism, since it was not
observed for loratadine. In contrast to its effects on
ECP, AZD3778 failed to affect the levels of tryptase,
which disagreed with the observation by Nakamura et
al. on mast cell stabilizing effects of a CCR3-antagonist
in a mouse model [20]. Differences between test sys-
tems, species, and the employed antagonists might
account for the discrepancy. AZD3778 as well as lorata-
dine also failed to reduce the allergen challenge induced
plasma exudation (a2-macroglobulin). Taken together,
our findings suggest that AZD3778 exerts a selective
anti-eosinophil effect. The observation is in keeping
with previous findings on such effects by CCR3 antag-
onism in experimental models [9-12,17-23], and extends
them to include allergic rhinitis. While reducing eosino-
phil activity in allergic rhinitis, the effect profile of
AZD3778 is different from what is expected for a topical
corticosteroid, which reduces all the employed lavage
fluid indices in the present model [25].
In the present study, AZD3778 exerted a moderate
anti-eosinophilic and symptom-reducing effect in aller-
gic rhinitis. We might not conclude that the effect on
nasal symptoms was secondary to anti-eosinophilic
actions associated with CCR3-antagonism. However, the
findings suggest that part of the symptomathology of
allergic rhinitis depends on eosinophil activity. Indir-
ectly, this is in agreement with observations on seasonal
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Figure 3 Tryptase (A), ECP (B), and a2-macroglobulin (C) in
lavages obtained late into the allergen challenge series prior
to and after bradykinin challenge (median values with
interquartile ranges). AZD3778 reduced the levels of ECP in
lavages obtained prior to as well as after bradykinin challenge (c.f.
placebo). Whereas this change reached borderline statistical
significance prior to bradykinin challenge (p = 0.08), it was
statistically significant after the challenge. In contrast to AZD3778,
loratadine failed to reduce the levels of ECP (c.f. placebo).
Furthermore, ECP recorded at AZD3778 treatment were significantly
lower compared to at treatment with loratadine. The treatments all
failed to reduce the lavage fluid levels of tryptase and a2-
macroglobulin (*Denotes p < 0.05 and ***denotes p < 0.001.)
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Page 7 of 9allergic rhinitis as a condition featuring particularly
intense eosinophil activity. For instance, eosinophil
degranulation (assessed by transmission electron micro-
scopy) is much greater in on-going allergic rhinitis than
in asthma [29]. Based on the present findings, and
observations by Erjefält et al. [29], it can be suggested
that interventions aiming at reducing eosinophil activity
in airway inflammation may better be evaluated in aller-
gic rhinitis than in asthma. Such intervention may
include IL-5 receptor antagonists, despite the fact that
trials with IL-5 active drugs (in asthma) have been dis-
appointing [30-32]. A specific area in which it may be of
interest to explore effects of anti-eosinophil active
drugs, notably CCR3-antagonists, is the interaction
between allergic/eosinophilic inflammation and the
common cold. For example, a series of observations
indicate the importance of rhinovirus infections to
exacerbations of asthma [33], and experimental inocula-
tion studies suggest that CC-chemokines and eosino-
phils may be involved in this interaction [34,35].
Conclusion
In summary, we conclude that AZD3778 exerts moder-
ately anti-eosinophilic and symptom-reducing effects in
allergic rhinitis. This effect can in part be attributed to
CCR3-antagonism.
List of abbreviations used
BMI: Body mass index; CCR3: CC-chemokine receptor-
3; ECP: Eosinophil cationic protein; GM-CSF: Granulo-
cyte-macrophage colony-stimulating factor; IL: Interleu-
kin; MCP-4: Monocyte chemoactive protein-4; PIF: Peak
inspiratory flow; RANTES: Regulated on Activation,
Normal T-cell Expressed, and Secreted; SQ-unit: Stan-
dard quantity unit; TNSS: Total nasal symptoms score.
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